Digital Therapeutics to Enhance Cognition in Major Depression: How Can We Make the Cognitive Gains Translate Into Functional Improvements?

Dr. Harvey has received research grants from the Stanley Medical Research Foundation and from Takeda; he has received consulting fees or travel reimbursements from Acadia, Alkermes, BioExcel, Boehringer Ingelheim, Karuna Pharma, Merck, Minerva, Otsuka, Regeneron, Roche, and Sunovion; he receives royalties for the Brief Assessment of Cognition in Schizophrenia; he is chief scientific officer of i-Function, Inc., has equity interest in i-Function and EMA wellness, and owns stock options in Mindstrong; he is compensated by Elsevier for service as an Editor-in-Chief; and he is on the board of Skyland Trail.